The Board of Directors approved the net financial position for the third quarter of 2026 (opens in a new tab), which was positive and amounted to 306,573 thousand euros.
The Board of Directors also took note of the progress of the principal clinical trials for Nidlegy™ and Fibromun, which are on track according to schedule, as well as the progress of other business activities. for Nidlegy™, the evaluation process for the Marketing Authorization Application (MAA) continues.